VEGFA and retinopathy of prematurity: This study included 50 patients, of whom 22 (44%) with type 1 ROP received intravitreal injections of anti-VEGF agents, 14 (28%) did not require any treatment for ROP (mild ROP), and 14 (28%) did not have ROP (control).